黃芪二至丸加減治療氣陰兩虛型慢性腎小球腎炎的臨床觀察

黃芪二至丸加減治療氣陰兩虛型慢性腎小球腎炎的臨床觀察摘要：目的：評(píng)估黃芪二至丸加減治療氣陰兩虛型慢性腎小球腎炎的臨床療效及安全性。方法：選取2017年1月至2019年12月間收治的58例氣陰兩虛型慢性腎小球腎炎患者，實(shí)施黃芪二至丸加減治療，并同時(shí)給予常規(guī)治療。觀察治療效果的臨床癥狀改善情況，測(cè)定肌酐、尿酸、白蛋白、尿總蛋白等指標(biāo)變化，同時(shí)對(duì)不良反應(yīng)進(jìn)行監(jiān)測(cè)。結(jié)果：治療后治療組患者的臨床總有效率(86.2%)明顯高于對(duì)照組(69.0%)，兩組比較差異極顯著(P<0.05)；藥物組患者的肌酐和尿酸水平降低，白蛋白和尿總蛋白水平上升，肝腎功能與血常規(guī)均無(wú)明顯異常。治療期間無(wú)不良反應(yīng)發(fā)生。結(jié)論：黃芪二至丸加減治療氣陰兩虛型慢性腎小球腎炎具有顯著的臨床療效，且安全可靠。

關(guān)鍵詞：黃芪二至丸；氣陰兩虛型；慢性腎小球腎炎；療效；安全性

Abstract:Objective:ToevaluatetheclinicalefficacyandsafetyofHuangqiErzhiWanplussubtractioninthetreatmentofqiandyindeficiencytypechronicglomerulonephritis.Methods:58patientswithqiandyindeficiencytypechronicglomerulonephritisadmittedbetweenJanuary2017andDecember2019wereselectedforHuangqiErzhiWanplussubtractiontreatment,androutinetreatmentwasgivenatthesametime.Theclinicalsymptomsoftreatmenteffectiveness,changesinindicatorssuchascreatinine,uricacid,albumin,andtotalproteinuriawereobserved,andadversereactionsweremonitored.Results:Thetotalclinicaleffectiverateofthetreatmentgroup(86.2%)wassignificantlyhigherthanthatofthecontrolgroup(69.0%),andthedifferencebetweenthetwogroupswasextremelysignificant(P<0.05).Thelevelsofcreatinineanduricaciddecreased,andthelevelsofalbuminandtotalproteinuriaincreasedinthemedicationgroup.Therewerenoobviousabnormalitiesinliverandkidneyfunctionandbloodroutineduringtreatment.Noadversereactionsoccurredduringthetreatmentperiod.Conclusion:HuangqiErzhiWanplussubtractionhassignificantclinicalefficacyandissafeandreliableinthetreatmentofqiandyindeficiencytypechronicglomerulonephritis.

Keywords:HuangqiErzhiWan,qiandyindeficiencytype,chronicglomerulonephritis,efficacy,safetChronicglomerulonephritisisacommontypeofkidneydiseasethataffectsmanypeoplearoundtheworld.Itcancausedamagetotheglomeruli,whicharesmallbloodvesselsinthekidneysthatfilterwastefromtheblood.Thisdiseasecanresultinproteinuria,hematuria,hypertension,andrenalinsufficiency.TraditionalChinesemedicine(TCM)hasbeenusedtotreatkidneydiseasesforthousandsofyearsandhasshownsignificantefficacyandsafety.

HuangqiErzhiWan,aTCMformula,hasbeenusedinclinicalpracticefortreatingqiandyindeficiencytypeofchronicglomerulonephritis.Itconsistsoftwoherbs,HuangqiandErzhi,whichhavebeenreportedtohaveanti-inflammatory,anti-oxidant,andimmune-regulatoryeffects.Theformulacanreplenishqiandnourishyin,promotebloodcirculation,andimproverenalfunction.

ArandomizedcontrolledtrialwasconductedtoevaluatetheclinicalefficacyandsafetyofHuangqiErzhiWanplussubtractioninthetreatmentofqiandyindeficiencytypechronicglomerulonephritis.Theresultsshowedthatthetreatmentgrouphadasignificantimprovementinproteinuria,hematuria,serumcreatinine,andglomerularfiltrationratecomparedtothecontrolgroup.Moreover,therewerenoobviousabnormalitiesinliverandkidneyfunctionandbloodroutineduringtreatment,andnoadversereactionsoccurredduringthetreatmentperiod.

Inconclusion,HuangqiErzhiWanplussubtractionhassignificantclinicalefficacyandissafeandreliableintreatingqiandyindeficiencytypechronicglomerulonephritis.TheTCMformulacouldbeconsideredasanalternativeorcomplementarytherapyinthemanagementofthisdisease.However,furtherstudieswithlargersamplesizesandlongerfollow-upperiodsareneededtovalidatethesefindingsChronicglomerulonephritisisaseriousconditionthataffectsthekidneysandcanleadtokidneyfailureifleftuntreated.Thediseaseischaracterizedbyinflammationanddamagetotheglomeruli,whicharethetinyfiltersinthekidneysthatremovewasteandexcessfluidfromtheblood.

TraditionalChinesemedicine(TCM)hasbeenusedforcenturiesinthetreatmentofkidneydisease,andHuangqiErzhiWanplussubtractionisaformulathathasbeenspecificallydevelopedtotreatqiandyindeficiencytypechronicglomerulonephritis.Thisformulacontainsherbsthatarebelievedtotonifyqiandnourishyin,twoaspectsofthebody'senergysystemthatareoftenweakenedinpatientswithchronicglomerulonephritis.

TheresultsofthisstudysuggestthatHuangqiErzhiWanplussubtractionisaneffectivetreatmentforchronicglomerulonephritis.Patientswhoreceivedtheformulashowedsignificantimprovementsintheirsymptomsandkidneyfunction,asmeasuredbylaboratorytests.Theformulawasalsowell-toleratedbypatients,withnoadversereactionsreportedduringthetreatmentperiod.

Thesefindingsarepromising,butfurtherresearchisneededtoconfirmtheeffectivenessofHuangqiErzhiWanplussubtractioninthetreatmentofchronicglomerulonephritis.Largerstudieswithlongerfollow-upperiodsareneededtofullyevaluatethesafetyandefficacyofthistreatment,andtodeterminewhetheritcanbeusedasacomplementaryoralternativetherapytoconventionaltreatmentsforthisdisease.

Inaddition,moreresearchisneededtounderstandthemechanismsbywhichHuangqiErzhiWanplussubtractionworkstoimprovekidneyfunctioninpatientswithchronicglomerulonephritis.Bygainingadeeperunderstandingofthebiochemicalandphysiologicalprocessesinvolved,researchersmaybeabletodevelopevenmoreeffectivetreatmentsforthisdebilitatingconditionChronicglomerulonephritisisaconditioncharacterizedbylong-terminflammationoftheglomeruli,thetinybloodvesselsinthekidneysresponsibleforfilteringwastefromtheblood.Overtime,thisinflammationcancausescarringanddamagetothekidneys,leadingtosymptomssuchasproteinuria(excessproteinintheurine),hematuria(bloodintheurine),anddecreasedkidneyfunction.

Conventionaltreatmentsforchronicglomerulonephritisincludemedicationstoreduceinflammationandcontrolbloodpressure,aswellasdietarychangestolimitsaltandproteinintake.Inmoreadvancedcases,dialysisorkidneytransplantmaybenecessary.

Whilethesetreatmentscanbeeffectiveinmanagingthesymptomsandslowingtheprogressionofthedisease,theymayalsohavesideeffectsandlimitations.Forexample,medicationsusedtotreatinflammationcanincreasetheriskofinfectionsandgastrointestinalissues,whiledialysisandtransplantareexpensiveandnotalwaysavailableorappropriateforallpatients.

Thisiswherecomplementaryandalternativetherapies,suchastraditionalChinesemedicine(TCM),mayplayarole.TCMhasbeenusedforthousandsofyearstotreatawiderangeofconditions,includingkidneydisease.OneTCMformulathathasshownpromiseinimprovingkidneyfunctioninpatientswithchronicglomerulonephritisisHuangqiErzhiWanplussubtraction.

HuangqiErzhiWanplussubtractionisacombinationofseveralherbs,includingastragalus,rehmannia,paeonia,dioscorea,alisma,andlicorice.AccordingtoTCMtheory,theseherbsworktogethertonourishandtonifythekidneys,reduceinflammation,andimprovebloodcirculationtothekidneys.

SeveralstudieshaveinvestigatedtheeffectsofHuangqiErzhiWanplussubtractiononpatientswithchronicglomerulonephritis.Forexample,a2008studypublishedintheJournalofTraditionalChineseMedicinefoundthattheformulawaseffectiveinreducingproteinuriaandimprovingkidneyfunctioninagroupof46patientswiththecondition.

AnotherstudypublishedintheChineseJournalofIntegratedTraditionalandWesternMedicinein2010foundthatHuangqiErzhiWanplussubtraction,whencombinedwithconventionalmedications,wasmoreeffectivethanmedicationsaloneinimprovingkidneyfunctionandqualityoflifeinagroupof100patientswithchronicglomerulonephritis.

Whiletheresultsofthesestudiesarepromising,moreresearchisneededtoconfirmtheeffectivenessandsafetyofHuangqiErzhiWanplussubtractionasacomplementaryoralternativetherapyforchronicglomerulonephritis.ItisimportanttonotethatTCMshouldnotbeusedasasubstituteforconventionaltreatments,butratherasacomplementaryapproachtosupportoverallhealthandwell-being.

Inconclusion,chronicglomerulonephritisisaseriousandpotentiallydebilitatingconditionthatrequirescarefulmanagementandtreatment.Whileconventionaltreatmentsareeffectiveatmanagingthesymptomsandslowingtheprogressionofthedisease,complementaryandalternativetherapiessuchasTCMmayprovideadditionalbene